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The use of human
umbilical cord artery
negates the need for
animal
experimentation












human aneurysmsAortic aneurysm rupture is a significant cause of premature mortality worldwide. Although animal
models exist, some frequently experience aortic rupture and sudden death. An alternative
approach is therefore required that would use human material to aid translation. Accordingly, we
present an optimized and validated protocol to isolate human umbilical cord arteries and their
subsequent deployment within a bioreactor. Consequently, this reproducible ex vivo human
model of aneurysm can be used for pathogenesis studies and accompanying assessment of
potential novel therapeutics.Bianco et al., STAR Protocols
1, 100108
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Aortic aneurysm rupture is a significant cause of premature mortality worldwide.
Although animal models exist, some frequently experience aortic rupture and
sudden death. An alternative approach is therefore required that would use hu-
man material to aid translation. Accordingly, we present an optimized and vali-
dated protocol to isolate human umbilical cord arteries and their subsequent
deployment within a bioreactor. Consequently, this reproducible ex vivo human
model of aneurysm can be used for pathogenesis studies and accompanying
assessment of potential novel therapeutics.
BEFORE YOU BEGIN
The establishment of the ex vivo model of aneurysm formation requires the bioreactor to be set up,
following these major steps:
Experimental Design Consideration
Timing: 2 h
1. Arrange umbilical cord delivery with the research nurse at the Maternity Hospital.
2. Arrange umbilical cord delivery with other research groups within the department.
3. Plan the experimental design in order to know how many chambers, lengths of tubing, and num-
ber of canulae are required.
4. Plan the conditions of scheduled treatments and interventions to be used and therefore the num-
ber of chambers that need to be set up.
5. Calculate the shear stress to be used. In abdominal aortic aneurysm (AAA) patients, the wall shear
stress is between 3.6 to 9.2 dyn/cm2. Accordingly, we use a wall shear stress of 6.5 dyn/cm2 in a
pulsatile laminar flow direction within the ex vivo model to ensure similar haemodynamic condi-
tions to the abdominal segment of the human aorta.
Preparation of Bioreactor Components
Timing: 2 h
6. Tubing, autoclave, and medium
a. Cut long silicon tubes into the correct length and connect to a stronger silicon tube. This addi-
tional strength is required to be used within the peristaltic pump. Connect all tubes together
with cannula at both ends and then autoclave.STAR Protocols 1, 100108, December 18, 2020 ª 2020 The Authors.

































Protocolb. Cut short silicon tubes, connect to cannula at both ends and then autoclave.
c. Autoclave water, forceps, and sylgard dishes.
d. Obtain Dulbecco’s Modified Eagle’s Medium (DMEM) and supplement with gentamicin,
penicillin, streptomycin, and L-glutamine.
e. Prepare a fresh formaldehyde.Assembly of Bioreactor
Timing: 30 min
7. Bioreactor
a. Place bioreactor chambers for at least 2 h in a Milton sterilizing solution, briefly wash in sterile
water and then place under a tissue culture hood to dry (Figure 1A).
b. Connect a long silicon tube at both ends to the bioreactor chamber (Figure 1B).
c. Connect two short silicon tubes to the inner edges of the bioreactor chamber (Figure 1C).KEY RESOURCES TABLEAGENT or RESOURCE SOURCE IDENTIFIER
ological Samples





emicals, Peptides, and Recombinant Proteins
giotensin II Enzo Life Sciences Cat#ALX-151-039
lbecco’s modified Eagle’s medium
MEM)
Sigma Cat#D5546
tal bovine serum (FBS) ThermoFisher Cat#10500-064
ntamicin Sigma Cat#G1397




earene (xylene substitute) Leica Cat#3803600
0% alcohol Leica Cat#3803686
tassium permanganate VWR Cat#26904.293
alic acid VWR Cat#0326-500G
illers elastin stain VWR Cat#351154S
n Gieson stain ThermoFisher Cat#LAMB-400-D
ayer’s hemotoxylin VWR Cat#1004710S
otts tap water Sigma Cat#S5134
sin Y VWR Cat#341972Q
rosirius red solution Abcam Cat#ab246832
drochloric acid Sigma Cat#320331
tric acid Sigma Cat#251275
X mounting medium Sigma Cat#06522
OXALL endogenous blocking solution Vector Labs Cat#SP-6000
(Continued on next page)
STAR Protocols 1, 100108, December 18, 2020
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
ImmEdge Pen Vector Labs Cat#H-400
Horse serum Vector Labs Cat#S-2000
Streptavidin, DyLight-488 conjugated Vector Labs Cat#SA-5488




Image Pro Plus v7.0 Media Cybernetics http://www.mediacy.com/
imageproplus
Image J NIH https://imagej.nih.gov/ij/
Other
Suture, Mersilk 5-0 black Ethicon Cat#W500H
Cannula, Male Luer Fitting for 1/16 inch ID
Tubing
World Precision Instruments Cat#13160-100
Wacker silicon tubing, ID 3.18MM, OD
6.35MM
VWR Cat#228-1094
Watson-Marlow Sci-Q 300 Series
Peristaltic Pump
ThermoFisher Cat#14-284-11
Minisart syringe filter VWR Cat#516-0907





Monoclonal anti-ER-TR7 antibody Bio-Techne Cat#NB100-64932
Horse anti-mouse biotinylated IgG
antibody
Vector Labs Cat#BP-2000
Goat anti-rat biotinylated IgG antibody Vector Labs Cat#BP-9400
Mouse IgG Vector Labs Cat#I-2000
Rat IgG Vector Labs Cat#I-4000
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OPEN ACCESSProtocolMATERIALS AND EQUIPMENT
CRITICAL: All preparatory procedures need to be performed within a Class II biologicalhood with standard aseptic technique.Serum Free Dulbecco’s Modified Eagle’s Medium (SFM)
Serum free Dulbecco’s Modified Eagle’s Medium (DMEM) is supplemented as detailed below. All
supplements are added using a Minisart syringe filter to prevent fungal and bacterial infections,
mixed well and finally stored at 4C.Media composition for Serum Free DMEM
Reagent Final Concentration Amount
Gentamicin 400 mL/500 mL 100 mL
Penicillin and Streptomycin 100 mL/mL and100 mL/mL 5 mL
L-glutamine 2 mM 5 mL
DMEM n/a 500 mL
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Figure 1. Bioreactor Set Up
(A) Bioreactor chamber under hood.
(B) Long silicon tube connected at both ends to the bioreactor chamber (see arrows).
(C) Two short silicon tubes connected to the inner edges of the bioreactor chamber (see arrowheads).
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OPEN ACCESS Protocol10% FBS/DMEM Culture Media
Serum free DMEM is supplemented with 50 mL fetal bovine serum (FBS) gold to obtain 10% FBS/
DMEM. FBS is the most common growth supplement used for the in vitro and ex vivo cell culture.
FBS has a high content of embryonic growth and therefore is always used for all our in vitro and
ex vivo studies.
All the components of 10% FBS/DMEM are listed below. FBS is added using a Minisart syringe filter
to prevent fungal and bacterial infections, mixed well and finally stored at 4C.Media composition for 10% FBS/DMEM
Reagent Final Concentration Amount
Fetal bovine Serum 10% 50 mL
Gentamicin 400 mL/500 mL 100 mL
Penicillin and Streptomycin 100 mL/mL and 100 mL/mL 5 mL
L-glutamine 2 mM 5 mL
DMEM n/a 450 mLBioreactor Components
A Watson-Marlow Sci-Q 300 Series Peristaltic Pump from Thermo Fisher is used to generate a wall
shear stress of 6.5 dyn/cm2 in a laminar flow direction to induce the ex vivo aneurysmal model. A
Wacker silicon tubing, ID 3.18MM, OD 6.35MM from VWR is used to connect either ends of the
bioreactor chamber. A Cannula, Male Luer Fitting for 1/16" ID Tubing from World Precision Instru-
ment is connected to the silicon tubing and then placed inside a supporting bioreactor chamber.
A Suture, Mersilk 5-0 black from Ethicon is used to tie the artery onto the cannula.
STEP-BY-STEP METHOD DETAILS
CRITICAL: Human umbilical cord samples must be obtained in compliance with institu-tional review board regulations and ethical guidelines. All procedures used for handling
human tissues should assume potential contamination of tissue with human pathogens
(HBV, HCV, HIV, C. difficile, etc.).Dissection of Arteries from Human Umbilical Cord
Timing: 2 h
This step details how to dissect the arteries from human umbilical cord (as shown in Figure 2).
1. Obtain human umbilical cords, covered under existing ethical approval.4 STAR Protocols 1, 100108, December 18, 2020
Figure 2. Method Detail
(A) Human umbilical cords were obtained from St Michaels’ Maternity Hospital.
(B) Arteries and vein were identified in umbilical cord cross-section.
(C) The cord is partially pinned down to permit further dissection.
(D) Arteries should be used immediately after dissection.
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OPEN ACCESSProtocola. Store umbilical cords in serum free media at 4C immediately after being obtained.
b. Dissect umbilical cord samples, limiting the time between harvest and usage within the biore-
actor setup to 90 G 30 min.
2. Human umbilical cords contain two arteries and one vein surrounded by Wharton jelly.
a. Under sterile conditions, place a length of umbilical cord within a sylgard petri dish.
b. Identify the two arteries and one vein by observing a cross-section of the umbilical cord.
3. Partially open the cord and pin down on the dish (a flat surface is required to work on).
4. Micro-dissect the arteries under phosphate-buffered saline (PBS, pH 7.4) containing penicillin
100 U/mL and streptomycin 100 mg/mL at 4C and flush with PBS to remove any possible blood
clots before transferring into serum free DMEM at 4C
5. Use the excised arteries immediately after the dissection to preserve vessel integrity andmaintain
experimental consistency.Ex Vivo Model of Aneurysm
Timing: 3 h
This step details how to set up the bioreactor system for the ex vivo aneurysm model
6. Sterilize tissue culture hoods with a Milton sterilizing solution
7. Place bioreactor chambers in Milton sterilizing solution for at least 2 h, then briefly wash in sterile
water and finally place under a tissue culture hood to dry.
8. Cut the arteries (stored in serum free DMEM at 4C) into three equal lengths of 5 cm to be used for
baseline, untreated, and treated conditions, respectively.
9. Connect the short silicon tubes at both ends of the bioreactor chamber.
10. Mount the arteries between two small cannulae, using sutures to double tie the artery onto each
cannula.
11. Connect each cannula to the short silicon tube and then place inside a supporting bioreactor
chamber.
12. Fill the long silicon tube with 10% FBS/DMEM and pass the tube through a peristaltic pump to
close the system and permit the induction of laminar flow within an incubator.
13. Subject each chamber to identical pulsatile flow conditions with a flow rate of 6.5 dyn/cm2 to
closely mimic abdominal aortic in vivo conditions, at 37C, 5% CO2 for 72 h.
14. As a control, use untreated chambers with 80mL of 10% FBS/DMEM. For Ang II-treated arteries,
supplement 80 mL of 10% FBS/DMEM with 5 mM Angiotensin II. For intervention-treated cham-
bers, add 80 mL of 10% FBS/DMEM with the corresponding intervention.
15. After 72 h of flow within the bioreactor chambers, carefully remove the arteries.
16. Remove and dispose of the two edges of the artery (not subjected to a laminar flow) where they
were sutured to the cannula. Cut the artery cut into two segments, to be named as proximal and
distal.STAR Protocols 1, 100108, December 18, 2020 5
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OPEN ACCESS Protocol17. Fix the proximal segment in 10% formalin and prepare for histology and store the distal segment
in a 80C freezer for downstream genomic/proteomic analysis.Histological Processing: Elastin van Gieson Staining
Timing: 3 h 30 min
18. The proximal portion of the artery (approx. 2.5 cm in length) should be cut into five 5 mm rings
for subsequent histological processing and wax embedding.
19. From the formalin-fixed wax-embedded arterial rings, cut 3 mm sections collected upon adhe-
sive glass microscope slides (two sections per slide).
20. To enable assessment of arterial elastin content, perform Elastin van Gieson (EVG) histochemi-
cal staining using an automated stainer (such as a Shandon Varistain 24-4 Automatic Slide
Stainer) or manual protocol (protocol details are shown in Table 1).
21. After EVG staining, coverslip sections using a relevant mounting medium (such as DPX) and visu-
alize the sections using a bright field microscope and acquire images under 320 magnification.
22. Determine the relative amount of elastin (which appears as black under a light microscope) using
a computerized image analysis program (such as Image Pro Plus or ImageJ) and express as an
average percentage of the arterial cross-sectional area.Table 1. Staining Protocol for EVG
Solution Incubation Time
Xylene substitute (such as
Clearene)
3 3 5 min
100% (v/v) alcohol (or
industrial methylated spirits)
3 3 5 min




Distilled water 3 min
1% (w/v) oxalic acid 5 min
Distilled water 3 min
70% (v/v) alcohol (or
industrial methylated spirits)
2 min
50% (v/v) Millers elastin stain
(VWR, Cat#351154S)
60 min
70% (v/v) alcohol (or
industrial methylated spirits)
2 min





100% (v/v) alcohol (or
industrial methylated spirits)
3 3 5 min
Xylene substitute (such as
Clearene)
3 3 5 minHistological Processing: Hematoxylin and Eosin Stain
Timing: 1 h 30 min6 STAR Protocols 1, 100108, December 18, 2020
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OPEN ACCESSProtocol23. From the formalin-fixed wax-embedded arterial rings, cut 3 mm sections collected upon adhe-
sive glass microscope slides (two sections per slide).
24. To enable assessment of arterial cellular content and general morphology, perform haematox-
ylin and eosin (H&E) histochemical staining using an automated stainer (such as a Shandon Va-
ristain 24-4 Automatic Slide Stainer) or manual protocol (protocol details are shown in Table 2).
25. After H&E staining, coverslip sections using a relevant mountingmedium (such as DPX) and visu-
alize the sections using a bright field microscope and acquire images under 320 magnification.
26. Count the number of nuclei and express as an average percentage of the arterial cross-sectional
area.Table 2. Staining Protocol for H&E
Solution Incubation Time
Xylene substitute (such as Clearene) 3 3 5 min
100% (v/v) alcohol (or industrial methylated
spirits)
3 3 5 min
Tap water 5 min
Mayer’s Haematoxylin 3 min
Distilled water 3 min
Scott’s Tap water 1 min
Running tap water 3 min
1% Eosin 1 min
Running tap water 3 min
100% (v/v) alcohol (or industrial methylated
spirits)
3 3 5 min
Xylene substitute (such as Clearene) 3 3 5 minHistological Processing: Picrosirius Red Staining
Timing: 4 h
27. From the formalin-fixed wax-embedded arterial rings, cut 3 mm sections collected upon adhe-
sive glass microscope slides (two sections per slide).
28. To enable assessment of arterial collagen content, perform picrosirius red (0.1% (w/v) Sirius Red
F3B saturated aqueous picric acid, pH 1.8–2.2) histochemical staining (protocol details are
shown in Table 3).
29. After picrosirius red staining, coverslip sections using a relevant mounting medium (such as
DPX) and visualize the sections using a bright field polarizing microscope and acquire images
under 320 magnification.
30. Determine the relative amount of collagen (which appears as red under a light microscope)
using a computerized image analysis program and express as an average percentage of the
arterial cross-sectional area. Qualitative analysis of fiber thickness/age is assessed by delin-
eating green and red fibers indicated under polarized light, as fiber color variation transits
from green to red proportional to the increase of fiber thickness/age. The relative amount
of each fiber color is expressed as a percentage of the total amount of collagen in the area
of interest.STAR Protocols 1, 100108, December 18, 2020 7
Table 3. Staining Protocol for Picrosirius Red
Solution Incubation Time
Xylene substitute (such as Clearene) 3 3 5 min
100% (v/v) alcohol (or industrial methylated
spirits)
3 3 5 min
Distilled water 3 3 2 min
Picrosirius red solution 0.1% (w/v) 90 min
0.01 N hydrochloric acid 2 3 15 s
Distilled water 2 3 2 min
Oven dry at 37C 80 min
100% (v/v) alcohol (or industrial methylated
spirits)
1 3 5 min




ProtocolCRITICAL: Ensure slides are dry before placing in 100% alcohol toward the end of thestaining, as any residual water will cause the Picrosirius Red stain to leach from the section.Histological Processing: Immunohistochemistry for Alpha-Smooth Muscle Actin and ER-TR7
Timing: 1 day
31. From the formalin-fixed wax-embedded arterial rings, cut 3 mm sections collected upon adhe-
sive glass microscope slides (two sections per slide).
32. To enable assessment of vascular smooth muscle cell phenotypic modulation and density, and
assess fibroblast presence, perform immunohistochemistry for alpha-smooth muscle actin
(aSMactin) and ER-TR7 expression, respectively.
Dewax sections by placing in three changes of Clearene for the duration of 5 min in each.
33. Rehydrate sections by placing in three changes of graduated alcohol (100%, 90% and 70%) for
the duration of 5 min in each.
34. Rinse in distilled H2O.
35. Place slides in a black trough with 10 mM citrate acid pH 6.0 (2.1 g/L distilled H2O)
36. 6 min full power in microwave
37. Top up with distilled water
38. 6 min full power in microwave
39. Top up with distilled water
40. Leave to cool for 30 min
41. Rinse in phosphate-buffered saline (PBS) for 3 3 2 min.
42. Dry back of slide with tissue paper and encircle sections with wax pen (ImmEdge Pen; Vector
Labs; cat#H-400), place within a humidified chamber and then inhibit endogenous peroxidase
activity with Bloxall endogenous blocking solution for 10 min at 18C–22C.
43. Rinse in PBS for 3 3 2 min, then pipette on 50 mL of 10% horse serum.
44. Incubate at 18C–22C for 30 min.
45. Tap off solution, dry back of slides and pipette on 50 mL of either mouse anti-human alpha-
smooth muscle actin (1/200) or rat anti-human ER-TR7 (1/250), diluted in PBS. Use same species
IgG diluted to same concentration as primary to act as a negative control.
46. Incubate for 16–18 h at 4C.
47. Wash sections in PBS for 3 3 2 min.
48. Dry back of slides with tissue and pipette onto sections 50 mL of either horse anti-mouse bio-
tinylated ready-to-use antibody (Vector Labs; cat#BP-2000) for alpha-smooth muscle actinSTAR Protocols 1, 100108, December 18, 2020
Figure 3. Summary of Our Ex Vivo Aneurysm Model
(A) Arteries isolated from human umbilical cords were mounted between two small cannulae within a bioreactor
chamber.
(B) The principle of the ex vivo model is delivery of laminar flow conditions (green arrow) alongside angiotensin II
within the artery to generate concentric dilatation (pink).
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OPEN ACCESSProtocoldetection, or goat anti-rat biotinylated ready-to-use antibody (Vector Labs; cat#BP-9400) for
ER-TR7 detection, diluted 1/200 in PBS.
49. Incubate at 18C–22C for 30 min.
50. Wash sections in PBS for 3 3 2 min.
51. Dry back of slides with tissue and pipette onto sections 50 mL DyLight-488-conjugated Strepta-
vidin (10 mg/mL; Vector Labs; cat#SA-5488).
52. Incubate at 18C–22C for 1 h.
53. Wash sections in PBS for 3 3 2 min.
54. Mount slides with appropriately sized coverslip and Vectashield antifademountingmediumwith
DAPI (Vector Labs; cat#H-1500) to enable the labeling of nuclei.EXPECTED OUTCOMES
Following the above method, we have developed (and characterized) a reproducible ex vivo model
of aneurysm formation with the use of human umbilical cord arteries stimulated with angiotensin II
within a bioreactor system (summarized in Figure 3). Angiotensin II (Ang II) infusion is the most
commonly used approach to induce aneurysm formation in animal models, especially mice, due
to its ability to promote aneurysm formation with the most comparable histological features to those
observed within human aneurysms (Sénémaud et al, 2017). Accordingly, angiotensin II infusion was
therefore selected for use in our ex vivo model. The concentration of Ang II was established on the
basis of previously published Ang II-infusion mouse model studies (Daugherty et al., 2000; Di Gre-
goli et al., 2017). Importantly, the dose used in our model was selected according to the range de-
tected in human aneurysmal disease. The circulating Ang II level within healthy human subjects is
between 4 and 15 pg/mL whereas AAA patients display plasma Ang II levels of 20–85 pg/mL. Within
the ex vivo bioreactor model a concentration of 65 pg/mL was used, which is within the range de-
tected in AAA patients.
Morphological and compositional changes typical of aneurysm formation havebeenwidely characterized
(Davies, 1998; Michel et al., 2011; Nordon et al., 2011), therefore a good model for aneurysm studies
should display such characteristics, which includes vessel dilatation, medial thinning, elastin degradation,
and loss of vascular smooth muscle cells.
As shown in Figure 4, umbilical cord arteries subjected to angiotensin II infusion for 72 h display
markedmacroscopically visible dilatation compared to apaired untreated control vessel. For the vali-
dation of our Ang II-infusion model, the umbilical cord artery was cut into three segments of equal
length. One portion was flushed with PBS and inserted into a bioreactor system at 6.5 dyn/cm2 usingSTAR Protocols 1, 100108, December 18, 2020 9
Figure 4. Representative Images of Ex Vivo Ang II-Infusion Aneurysm Model after 72 h within a Bioreactor
Macroscopic changes in vessel dilatation were observed after 72 h within a bioreactor plus angiotensin II infusion
compared to untreated control paired artery, assessed (A) while still within the bioreactor or (B) after histological
sectioning and H&E staining.
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OPEN ACCESS Protocolmedia containing 5 mMAng II in order to replicate the well-characterized mouse model of aneurysm
formation. An equally sized length of the same umbilical cord artery was placed in the bioreactor sys-
tem for 72 h at 6.5 dyn/cm2 with media alone and served as a paired control, termed untreated.
To ensure that the observed macroscopic changes were indicative of dilatation and therefore aneu-
rysm formation, further histological examination was performed, as required to validate the model.
As previously mentioned, the principle morphological and compositional characteristics associated
with aneurysm formation were assessed, including vessel dilatation, medial thinning and associated
elastin loss, and decreased medial vascular smooth muscle cell (VSMC) density.
As shown in Figure 5, Ang II infusion for 72 h under pulsatile laminar flow conditions demonstrated
that the total vessel area (an indicator of dilatation) was significantly increased in Ang II-treated um-
bilical arteries (90%; P<0.05; n=6) compared to untreated paired control arteries. In addition, a sig-
nificant reduction in umbilical artery medial thickness (49%; P<0.05; n=6), medial elastin content
(60%; P<0.05; n=6), and medial cell density (32%; P<0.05; n=5) was observed in Ang II-treated um-
bilical arteries compared to paired untreated vessels. In summary, the above observations demon-
strate our novel ex vivo bioreactor system employing arteries retrieved from human umbilical cord
and subjected to Ang II administration, develops similar morphological and compositional changes
associated with aneurysm formation as those observed in human aneurysms and mouse models.
Assessment of these changes should be undertaken to validate the correct experimental setup of
the model in new laboratory settings.
Two additional related key indicators of aneurysm formation are VSMC phenotypic modulation and
increased collagen turnover. VSMC modulation from a contractile phenotype to a synthetic form is
characterized by a loss of contractile markers such as alpha-smooth muscle actin (aSMactin), which
can be observed in umbilical cord arteries after Ang II administration within our ex vivo bioreactor
model (Figure 6). However, very few fibroblasts (ER-TR7 positive) were detected (Figure 6).
Increased collagen turnover is most commonly presented as a reduction in arterial wall total collagen
content. Accordingly, analysis of picrosirius red stained sections and subsequent quantification dem-
onstrates a reduction of total fibrillar collagen content (32%; P<0.05; n=5; Figure 7) is an additional
robust marker and validative indicator of aneurysm formation within our ex vivo bioreactor model.LIMITATIONS
This model accurately reproduces key histological disease features observed in well-characterized
animal models and the human pathology of aortic aneurysms, including vessel dilatation alongside
compositional changes such as medial thinning, elastin degradation, and loss of VSMC content.10 STAR Protocols 1, 100108, December 18, 2020
Figure 5. Effect of Ang II Administration on Arterial Vessel Dilatation, Medial Thickness, Elastin Content, and
Medial Cell Number
Quantification and representative images of (A) vessel dilatation, (B) medial thickness, (C) elastin content, and (D)
number of medial cells assessed in ten 320 magnification fields of EVG stained sections from human umbilical cord
arteries after insertion within a bioreactor for 72 h without Ang II (untreated) and with Ang II (Ang II). Data are
expressed as a fold change in Ang II-infused arteries compared to control (untreated) vessels (data are presented as
mean G SEM; n = 6). ***p < 0.001, *p<0.05 versus control, 2-tailed Student paired t test. Scale bar represents 250 mm
in (A) and 50 mm in (B)–(D).
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OPEN ACCESSProtocolA potential limitation of the current model is the use of human umbilical cord arteries rather than the
use of a human abdominal aorta. However, the structure and composition of the umbilical cord
artery is similar to other arteries and it consists of three concentric layers: intima, media, and adven-
titia. The only marked difference is that umbilical arteries (similar to pulmonary arteries) carry deox-
ygenated blood which travels back to the placenta to be re-oxygenated again by the mother. The
deoxygenated nature of the blood vessel (rather than oxygenated as is the case with the aorta)
may affect the specific response to aneurysm inducers. However, the agreement in effects of Ang
II on arterial changes in morphology and composition, between the ex vivo model and both human
aneurysms and the currently available mouse models suggest a high degree of similarity. As such,
human umbilical cord arteries represent a good alternative to human aortic tissue and are more
readily available for use in aneurysm research experiments. Considering the majority of human
abdominal aortic aneurysms display super-imposed atherosclerosis and marked inflammatory cell
accumulation (Davies, 1998; Michel et al., 2011; Nordon et al., 2011), an additional limitation of
the ex vivo model could be the absence of atherosclerosis-related inflammation. However, this is
also a caveat with most mouse models of aneurysm and does not limit their use or publication in
high impact journals. Moreover, the main intention of the ex vivo model is to replicate and ideally
replace current animal models of aneurysm, while also providing a more translational platform
through the use of human tissue.STAR Protocols 1, 100108, December 18, 2020 11
Figure 6. Effect of Ang II Administration on Arterial VSMC aSMactin and ER-TR7 Immunopositivity
Representative images of immunohistochemistry for (A and B) alpha-smooth muscle actin (aSMactin; green color)
alongside a DAPI nuclear label (blue), or (C and D) ER-TR7 (green color) alongside a DAPI nuclear label (blue), in
sections from human umbilical cord arteries after insertion within a bioreactor for 72 h without Ang II (untreated; A and




The ethics used during the development of this model and its subsequent validation covered pro-
jects from three different research groups. As such, there are occasions when human umbilical cords
are shared between research groups, which can limit both the size and volume of samples. For
example, a specific number of umbilical cords permitted to be retrieved and used in research under
the ethical permission can hamper large experiments.
Potential Solution 1
If possible, have project-specific ethics in place which will allow use of the full length of the umbilical
cord and ensure enough samples can be collected to fulfill the project requirements.
Problem 2
The cross-section thickness of the umbilical cord artery can be different between donors as well as
between arteries from the same umbilical cord.
Potential Solution 2
We have to use a single umbilical cord artery and generate multiple segments from it at one time for
control and intervention experiments. This will enable paired statistical analysis and reduce the intra-
group variability resulting from the use of two different arteries of the same umbilical cord.
Problem 3
During the setup of the model, the small silicon tube is connected with a cannula to the umbilical
cord artery within a chamber system. The chamber system is then connected at two points to a
long silicon tube that is attached to the peristaltic pump. These factors are important to close the
system and permit the induction of laminar flow within an incubator. If the arterial wall is damaged
or the artery is not tied appropriately to the cannula, there will not be any laminar flow.12 STAR Protocols 1, 100108, December 18, 2020
Figure 7. Ang II Administration Significantly Reduced Human Umbilical Cord Artery Fibrillar Collagen Content
Compared to Untreated Control Arteries
Quantification and representative images of total fibrillar collagen content assessed in ten 320 magnification fields of
Picrosirius red stained sections from human umbilical cord arteries after insertion within a bioreactor for 72 h without
Ang II (untreated) and with Ang II (Ang II). Data are expressed as a fold change percentage in total collagen content of
the Ang II-infused arteries compared to control (untreated) vessels (data are presented as mean G SEM; n = 6).
**p < 0.01 versus control, 2-tailed Student paired t test. Scale bar represents 100 mm and is applicable to both panels.
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OPEN ACCESSProtocolPotential Solution 3
In order to create consistent laminar flow, the arteries should be double tied at the two end points
using appropriate surgical suture. If the arterial wall is damaged during this process, the damaged
section should be discarded, and a new section of the same artery should be used.RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the Lead Contact, Jason Johnson (jason.l.johnson@bristol.ac.uk).Materials Availability
This study did not generate new unique reagents.Data and Code Availability
This study did not generate any unique datasets or code.ACKNOWLEDGMENTS
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